Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 7/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31033194 | 1.00 | MEN1 (0.86) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| SCHEMBL16621435 | 0.81 | SCN7A (0.60) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| SCHEMBL16621374 | 0.79 | SCN7A (0.58) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| SCHEMBL4536226 | 0.79 | SCN7A (0.58) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| SCHEMBL30117493 | 0.77 | MEN1 (0.55) | MEN1MAPTKMT2ALTA4HTDP1 | |
| SCHEMBL16621316 | 0.76 | MEN1 (0.58) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| SCHEMBL25715589 | 0.76 | SCN7A (0.55) | MEN1MAPTKMT2ASCN7ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL18109825 | 0.76 | SCN7A (0.55) | MEN1MAPTKMT2ASCN7ALTA4H | |
| SCHEMBL31143565 | 0.75 | LTA4H (0.71) | TSHRLTA4HTDP1 | |
| SCHEMBL25274425 | 0.75 | SCN7A (0.54) | MEN1MAPTKMT2ASCN7ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | MEN1 2990/4885MAPT 2519/4885KMT2A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.